ORIC PHARMACEUTICALS, INC. Operating Lease, Payments
ORIC PHARMACEUTICALS, INC. (ORIC) reported Operating Lease, Payments of $3.31 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-02-23
- ORIC PHARMACEUTICALS, INC. operating lease, payments for the quarter ending 2021-12-31 was $400.00K.
- ORIC PHARMACEUTICALS, INC. operating lease, payments for the quarter ending 2021-09-30 was $500.00K.
- ORIC PHARMACEUTICALS, INC. operating lease, payments for the quarter ending 2021-06-30 was $500.00K.
- ORIC PHARMACEUTICALS, INC. operating lease, payments for the quarter ending 2021-03-31 was $500.00K.
- ORIC PHARMACEUTICALS, INC. operating lease, payments for fiscal 2025 was $3.31M, a 13.29% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. operating lease, payments for fiscal 2024 was $2.92M, a 5.88% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. operating lease, payments for fiscal 2023 was $2.76M, a 25.60% increase from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. operating lease, payments for fiscal 2022 was $2.19M, a 15.53% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $3.31M 10-K · filed 2026-02-23 | ||||
| 2024-12-31 | $2.92M 10-K · filed 2026-02-23 | ||||
| 2023-12-31 | $2.76M 10-K · filed 2025-02-18 | ||||
| 2022-12-31 | $2.19M 10-K · filed 2024-03-11 | $2.20M 10-K · filed 2023-03-16 | |||
| 2021-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $900.00K derived: sum of 2 quarters · filed 2023-03-16 | $1.40M derived: sum of 3 quarters · filed 2023-03-16 | $1.90M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $1.00M derived: sum of 2 quarters · filed 2021-11-08 | $1.50M 10-Q · filed 2021-11-08 | ||
| 2021-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $1.00M 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $500.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |